Public Health Norfolk urges older residents to feel connected - Norfolk County Council

Riversyde 83 volunteers Johanna Cousineau, left, and Adele Haverkamp at the 2026 Norfolk Applefest on Argyle Street. Chris AbbottEditorThe third annual Norfolk Applefest on Sept. 26 was well-attended from start to finish this year. “Right at 11 a.m. we were very busy, right from the start,” said Downtown Simcoe BIA coordinator Les Anderson, pleased with the festival turnout on Argyle Street from 11 a.m. to 3 p.m. on Saturday, Sept. 26. “It’s still going well. “People seem to be quite happy. Can’t go wrong with Andy the Balloon Guy,” Anderson added with a laugh. Along with the family entertainment, including facepainting, there were apple-theme treats. Many of the vendors highlighted apples – from apple slushies at the ABEL Enterprises food truck to apple crisp and apple tarts from Riversyde 83, to baskets of free apples – along with some usual festival food/beverage selections, including an ice cream truck. “We partnered with the Norfolk County Fair & Horse Show for this event as well,” said Anderson, noting the fair provided prizes for the Applefest storefront decorating contest, which had 19 entries this year.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.